Clinical Study

D5336c00001- Assess The Safety And Efficacy Of Agents Targeting Dna Damage Repair In Combination With Olaparib Versus Olaparib Monotherapy In The Treatment Of Metastatic Triple Negative Breast Cancer Patients Stratified By Alterations In Homologous Recomb

Posted Date: Jun 4, 2019

  • Investigator: Neetu Radhakrishnan
  • Specialties: Breast Cancer, Oncology
  • Type of Study: Drug

This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (AZD6738) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (AZD1775)

Criteria:

Triple Negative Breast Cancer, Stage Iv, In Second Or Third Line Setting ,Stratified By Presence/Absence Of Qualifying Tumour Mutations In Genes Involved In The Hrr Pathway.

Keywords:

Brca, Triple Negative Breast Cancer, Hrr

For More Information:

Missy Racic
5135846628
marcumma@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.